1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

01 Nov 2023
Admin
News Article

NurExone Biologic Secures FDA Orphan-Drug Designation to Expedite Development of ExoPTEN Therapy for Treating Acute Spinal Cord Injuries

NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), a leading biotechnology company, is delighted to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for its innovative therapy, ExoPTEN. This designation recognizes the therapeutic potential of ExoPTEN for acute spinal cord injury, a condition with limited treatment options.

Orphan drug designation provides valuable benefits to pharmaceutical companies working on treatments for rare diseases, which are defined as those affecting fewer than 200,000 people in the United States. These benefits encompass market exclusivity, financial incentives, regulatory support, and assistance in the drug development process. Overall, this designation encourages and supports the development of specific therapies, ultimately increasing access to treatments for patients.

Securing orphan-drug designation is a significant achievement for NurExone. This designation pertains to the use of small extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) loaded with short and modified interfering RNA (siRNA) targeting the phosphatase and tensin homolog (PTEN) protein for the treatment of acute spinal cord injury, as incorporated in NurExone's ExoPTEN drug, which is currently in development.

"Obtaining orphan-drug designation is expected to simplify our path to market, shorten the regulatory process, resulting in substantial cost savings for the company, and grant valuable market exclusivity. We are grateful for the official recognition of the potential impact of our therapy on the lives of patients coping with acute spinal cord injuries," stated Dr. Shaltiel, CEO of NurExone Biologic, Ltd.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!